Diabetes Medicine Enhances Risk of Heart Attack Privacy Policy | Contact |

Diabetes Medicine Enhances Risk of Heart Attack

BBBOnLine Reliability Seal

Home - Health Insurance - Health Insurance Resources - More Resources - Diabetes Medicine Enhances Risk of Heart Attack

Find Local Doctors & Health Plans : Enter Your ...

ZIP Code

Quotes Type

Your E-mail ID

[Optional and Compliant to Federal Laws]


Diabetes Medicine Enhances Risk of Heart Attack

Diabetes Medicine Enhances Risk of Heart Attack

A normal diabetes medicine enhances the risk of heart attack in comparison to similar drug as revealed by a new research.

The study report, published on the bmj.com has shown that rosiglitazone increase the chance of heart failure as well as death among the older patients in comparison to pioglitazone.

Both rosiglitazone and pioglitazone belong to a group of medicines known as thiazolidinediones which is widely used for treatment of the type 2 diabetes. Both the medicines help maintaining the levels of blood sugar. However, both of them cause adverse side effects that may include fluid retention, weight gain and heart failure.

It is still in question that whether there is clinically significant difference in cardiac safety between rosiglitazone and pioglitazone. And, so research fellows in Canada have compared the chance of heart failure, heart attack as well as death in the patients treated with rosiglitazone and pioglitazone.

Comparing the prescription records, boffins has identified about 40,000 older patients from the age group of 66 and above that have been treated with either pioglitazone or rosiglitazone; between April'02 and March '08.

Data on hospitalization for either heart failure or heart attack during six years long study time were noted; while the number of deaths has been identified from a nationwide database.

In-depth investigation revealed that patients who were treated with pioglitazone had a noticeable lower rate of heart failure as well as death in comparison to the patients treated with the rosiglitazone. However, there was no such noticeable difference in risk of cardiac attack.

The research fellows evaluate that for each 93 diabetic patients treated with the rosiglitazone instead of pioglitazone, one more cardiovascular phenomenon or death would be anticipated to take place, per year.

The authors say that result of their study found clinically significant differences in cardiovascular safety characteristics of pioglitazone and rosiglitazone in medical practice.

They conclude that specified the accumulating facts of risks with rosiglitazone treatment and lack of a separate medical benefit for the medicine over pioglitazone, it's sensible to ask whether continuing use of rosiglitazone is right.

Diabetes Medicine Enhances Risk of Heart Attack  Get Your Free Medical Insurance Quotes Now!


Home     Contact Us     Privacy Policy     Our Edge     Disclaimer     Site Map     More Resources

Copyright 2003-2018 QuickHealthInsurance.com Group, Inc. [Protected under U.S. Copyright TX5-874-987 & Several Pending Patents]

Page copy protected against web site content infringement by Copyscape.